CRISPR Therapeutics AG Website

CRISPR Therapeutics AG

NasdaqGM-CRSP

Company Overview

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

  • Name

    CRISPR Therapeutics AG

  • CEO

    Samarth Kulkarni

  • Website

    www.crisprtx.com

  • Sector

    Biotechnology

  • Year Founded

    2013

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • Partnerships allow Crispr Therapeutics to receive milestones and economic benefits from drug candidate progression while offsetting some of the clinical development costs.

  • Crispr Therapeutics' Crispr/Cas9 platform has the potential to develop highly efficacious and curative treatments for rare, genetic diseases with high unmet needs, which will likely lead to pricing power.

  • Crispr's diverse pipeline with lengthy patents has the potential to become strong intangible assets if successful in trials and regulatory approvals.

Bears Say

  • Much of Crispr Therapeutics’ pipeline is in the early stages of development and years away from potentially receiving approval.

  • Crispr Therapeutics is an emerging gene editing company, and there are many other companies also investing in novel gene editing therapies, which could create competitive pressure.

  • Crispr Therapeutics' very high level of uncertainty highlights the risks associated with its early-stage pipeline and the range of potential outcomes for the company.

Source: Morningstar Analysis - Nov 11, 2025

What's happening

Nov 12, 2025 - Dec 12, 2025

CRISPR Therapeutics AG Surges on FDA Approval and Clinical Success

  • CRISPR Therapeutics AG received FDA approval for its product Casgevy, enhancing its position in gene editing therapies.
  • Positive clinical trial results for Casgevy have bolstered investor confidence amidst market fluctuations.
  • Despite temporary bearish sentiments due to rumors and analyst adjustments, the overall performance remains strong.

Over the past month, CRISPR Therapeutics AG (CRSP) experienced a notable increase of 4.3%, significantly outperforming the S&P 500's return of 0.7%. This performance underscores CRSP's resilience in a challenging market environment. A key driver for this upward trend was the early December FDA approval of Casgevy, which solidified its leadership role in gene editing therapies. The positive sentiment surrounding this regulatory endorsement has been further supported by promising clinical trial results presented at significant conferences.

On December 8th, CRSP shares rose by 3.2% following news that Vertex Pharmaceuticals' Casgevy therapy achieved critical milestones in trials targeting blood disorders such as sickle cell disease and beta thalassemia. This development not only enhances commercial prospects but also reinforces investor confidence regarding CRSP’s competitive standing within the biotech sector. Analysts noted that while other therapies from competitors gained attention at recent conferences, they did not pose a substantial threat to CRISPR's market share.

However, earlier bearish sentiments impacted stock performance temporarily during November; specifically on December 1st when rumors about potential merger activities led to a decline exceeding 4%. Additionally, Chardan Capital adjusted its price target downward around late November due to cautious outlooks on valuation while maintaining a "Buy" rating on the stock.

Despite these fluctuations driven by external factors—such as concerns over insider purchases and broader market fears—CRSP maintained an overall bullish trajectory throughout most of December with several days showing significant gains attributed to strategic acquisitions and strong institutional interest from figures like Cathie Wood. Overall performance reflects an impressive outperformance against both the S&P 500 index as well as the Health Care sector (XLV), where it exceeded sector returns by approximately 2.4%.

NasdaqGM:CRSP